ENUM .0068 MERCK: collaboration with a leading immuno-oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cellular responses to therapies being developed by Merck – R&D funding and undisclosed milestone payments – Merck has exclusive rights to data related to its proprietary compounds – ENUM has achieved first milestone in the collaboration – Expanded scope of work to include non-small cell lung cancer • NCI: awarded Phase 2 contract in September 2014 for ~$1 million over two years – Automation of human tissue immuno-oncology profiling – Opens door to broader pipeline and potentially accelerated development – Collaboration with leading scientists: – Jedd Wolchok’s group at MSKCC - genetic basis for response to checkpoint inhibitors and novel immunotherapeutics – Doug Kwon’s group at MGH/Ragon Institute - pioneering techniques for single cell immune cell analysis in biopsy
Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.